What Granules India Doubters Got Wrong

If you only glanced at Granules India’s recent quarterly figures, with revenue and profit both higher and net margin stepping up from 9.3% to 12.2%, the share price outcome might still surprise you. Investors who held Granules India over the past year are up 41.8%, including dividends. If you had been weighing up a position back in October 2025, what exactly in the competing bull and bear arguments could have justified taking that risk?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

The easy part of this move is behind Granules India. Zero in on 188 high quality undervalued stocks for companies trading below our estimates.

The Two Granules India Stories Investors Had To Weigh

The shares cost ₹568 at the start of the period, so any Granules India thesis had to clear that bar before it was worth the risk.

The bullish narrative put fair value at ₹700. It leaned on revenue growth of 17.6% a year and an assumed profit margin of 13.0%, supported by expansion into high value generics, oncology, peptides and CDMO.

The bearish view set fair value at ₹480. That camp still used 15.3% annual revenue growth and a 13.1% margin, and highlighted concerns about peptide CDMO overcapacity, higher leverage and sustained regulatory and compliance costs.

What The Results Changed For The Granules India Thesis

Granules India posted Q1 2027 revenue of ₹14,767.74m and net income of ₹1,799.63m, with net margin rising from 9.3% to 12.2%. That margin improvement supported the bullish focus on profitability, although the level still sat short of the 13.0% to 13.1% assumptions. Overall, the evidence cut both ways for the earlier forecasts.

The key assumption here was margin expansion. When you test a story like this at another company, track whether net income and net margin actually move toward the level implied by the P/E you are paying.

What Granules India’s New Price Asks You To Believe

Granules India now trades at ₹807, after a 41.8% gain over the past year from ₹568. The selected Narrative’s Fair Value sits below the current price, based on concerns about how expansion and capital intensity translate into future earnings quality.

At today’s price you are effectively assuming that expansion into peptides, CDMO and complex generics converts heavy investment into durable margins. The key question is how the selected Narrative’s worries about overcapacity, higher compliance spend and concentration in key molecules challenge that belief.

"Expansion into the peptide CDMO and therapeutics market through acquisitions like Senn Chemicals has significantly increased capital employed and leverage, but industry overcapacity, extended gestation periods for CDMO projects, and intense competition from well-established global peers could delay expected revenue contributions and profitability, weighing on ROCE and suppressing earnings for several years."

The price and this Narrative do not agree. → Uncover what this Narrative says Granules India is actually worth

Granules India And A Different Kind Of Drug Engine

Granules India shows how manufacturing scale and cost control can anchor a story. Yet your next question might be about demand, not supply at all.

Weight management and diabetes treatments are reshaping how people think about chronic disease. One global specialist focuses almost entirely on injectable therapies that target these conditions.

This other business leans on a few powerful drugs to drive results. Once a treatment clears development, each additional dose can become highly profitable.

The same patients using basic ingredients from firms like Granules India may later rely on advanced medicines from this specialist. As those therapies reach more conditions, that reliance could deepen in unexpected ways.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 15% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com